SXTP 60 Degrees Pharmaceuticals Inc

$SXTP Dont worry $SLS trades at 2.3 Billion market cap with Zero fda approved drug. We have fda approved drug, 2.6million share float, and data due Tues. Data chasers will come

$SXTP 2 put in perspective $SLS trades at 2.3 Billion market with No fda approved drug. We have fda approved drug with data tomorrow

$SXTP No significant run before data release. If data is good, there will not be sell the news movement.

$SXTP Just a wild guess outside of traders possibly jumping in, I wouldn't be surprising if Knight Therapuetics was buying raising their stake to own more shares so to reduce the amount of shares needed for a takeover bid. Just a gut feeling. Good luck to all next week.

$SXTP last time red chip was on this was Jan. when it ran huge will be on CNBC and Bloomberg over the weekend, also presenting data Tuesday Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis (NCT06207370) to be disclosed on October 6, 2026.

$SXTP announces interim data release and KOL webinar on Oct 6 for its severe babesiosis study.

$SXTP Great results so far. Wasn’t expecting announcements until January but it must be better than expected so they decided to do it earlier. Still need final FDA approval and expect it to happen. At least we have eyes on the stock again and should see positive price action moving forward.

$SXTP is moving on clinical trial results following a Globe Newswire release. 60 Degrees Pharmaceuticals reports all five completed expanded access babesiosis patients showed clinical improvement and negative PCR results with tafenoquine-atovaquone treatment. RTPR pushed this release out to users at 8:06:00 AM ET

$SXTP 60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients

$SXTP 60 degrees pharmaceuticals plans january 2027 hospitalized babesiosis data readout; will seek pre-snda meeting with fda

$SXTP Look for the latest 8-k report. News are there. No interim data for today, study stays blinded. I'm out until January.

$SXTP provides an updated investor presentation and a press release on its Jan 2027 hospitalized babesiosis data readout.

$SXTP Fda approved drug, more likely the tick drug on the way... trades at 5 million market cap. Data due today SLS zero Fda drugs approved trades at 2.3 Billion market cap $SLS

$SXTP Who saw that short spike up to 1.82 but than got hammered down back to 1.55?? There trying to hold it down for now

$SXTP added the dip, presenting data Tuesday Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis (NCT06207370) to be disclosed on October 6, 2026

$SXTP I don’t see this as a flip for Knight Therapeutics but rather a long term investment or more likely a takeover candidate with any positive FDA approval for the drug. We will find out next week.

$SXTP it’s almost breaking out. I bought some at 1.23 but I prefer it to close above 1.33 for breakout to confirm

$SXTP Someone really wanted to hop in. Tomorrow might be the data release day. Any good thoughts if Interim data is success?

Today's biggest catalyst moves on the wire (validated intraday captures through 5:15 PM ET): $SXTP ran as much as +40% — partnership $AIBT ran as much as +39% — product launch $BEAT.X ran as much as +39% — clinical trial results $GMAB ran as much as +33% — clinical trial results $PODC ran as much as +28% — M&A / acquisition Get real-time catalyst alerts using RTPR.

$SXTP 10:37 on Oct. 28 2026 60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal Syndrome #tradeideas